The current price of ARCT is $9.36 — it has decreased by 13.89% since the previous close. Data as of Nov 5, 2026.
ARCT is down 20.75% over the past week, down 36.15% over the past month and up 8.33% over the past year. The price is above its 200-day moving average of $9.04.
Analysts' average 12-month price target for ARCT is $30.50, which implies 225.85% upside from the current price. Individual estimates range from $20.00 to $41.00.
Of the 13 analysts covering Arcturus Therapeutics Holdings Inc., 1 rates it a strong buy, 10 rate it a buy and 2 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Arcturus Therapeutics Holdings Inc. has a market capitalization of $266.04M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Arcturus Therapeutics Holdings Inc. posted a loss of $0.84 per share against an estimate of -$0.9964, beating expectations by 15.70%. Upcoming reports are listed in the earnings calendar.
Arcturus Therapeutics Holdings Inc. reported revenue of $2.96M in its most recent quarter, which has decreased by 89.54% compared with the same quarter a year earlier. Analysts had expected $3.11M.
Arcturus Therapeutics Holdings Inc. has not paid any dividends over the past year.
Companies most comparable to Arcturus Therapeutics Holdings Inc. include Vir Biotechnology, Inc., Novavax, Inc., Silence Therapeutics plc, Arbutus Biopharma Corp and Valneva SE.
In the latest trading session ARCT moved between $9.31 and $10.61, a range of 13.89% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Arcturus Therapeutics Holdings Inc. shows a strong sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Arcturus Therapeutics Holdings Inc. is strong sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks ARCT has traded between $5.50 and $17.96. The current price is 47.88% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.